Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics PLC FD off to new pastures

“Ian leaves the company in the strongest position it has ever been in, in terms of sales, cash balance and growth potential...”
Allergy Therapeutics PLC FD off to new pastures
Finance director has been at Allergy for 14 years

Allergy Therapeutics’ (LON:AGY) finance director Ian Postlethwaite is to leave to take another post elsewhere.

He will stay in the position for up to six months while the hay fever vaccine group finds a replacement.

Peter Jensen, Allergy Therapeutics’ chairman said: "Ian has been the Finance Director for 14 years and a significant contributor to the success of the company.

“During this time Allergy Therapeutics has listed on AIM, achieved a number of financial goals including two fund raisings in 2015 to support the Company's clinical and other development plans, and has growing revenues from products on sale in Europe.

“Ian leaves the company in the strongest position it has ever been in, in terms of sales, cash balance and growth potential.” 

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Newswire
October 10 2016

Related Articles

AZN2.jpg
January 10 2017
We look at what looks to be a savvy investment by the UK biotech.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
picture of someone with head pain
December 07 2016
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.